Project Grant R41HL134387

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a $560,000 research initiative led by Baylor College of Medicine to develop a "triple gene therapy" treatment for ischemic heart failure. The goal is to leverage a combination of three experimental approaches - inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing angiogenesis - to synergistically regenerate...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $833,594 to investigate the pro-regenerative potential of the Pontin gene in the heart. The research aims to decipher the gene regulatory networks controlling cardiomyocyte (heart muscle cell) proliferation, with the goal of identifying druggable pathways to stimulate heart regeneration as a remedy for myocardial infarction....

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $693,261 to Baylor College of Medicine to investigate the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The key objectives are to gain insights into gene therapy strategies that knock down Hippo signaling in cardiac tissue following myocardial infarction, with the goal of improving cardiac function in mouse models of ischemic...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $496,367.00 to Duke University to support research on novel approaches for cardiac reprogramming. Specifically, the project aims to improve the efficacy of in-situ reprogramming of scar fibroblasts into cardiomyocytes through three key objectives: Investigating the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing...

This Project Grant award of $1,290,338 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research conducted by Jaan Biotherapeutics, Inc. to develop a gene therapy treatment for heart muscle regeneration after myocardial infarction. The research aims to inhibit four specific microRNAs that regulate cardiomyocyte dedifferentiation, proliferation, and redifferentiation, with the goal of stimulating endogenous heart muscle regeneration and...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded Revidia Therapeutics, Inc. a $1,358,179 Project Grant to conduct IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436. This novel therapy aims to treat fatal cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a leading cause of mortality in this population. The proposed studies will...

Khloris Biosciences, Inc. received a $3.46 million Project Grant from the National Institutes of Health National Heart, Lung and Blood Institute to develop and validate a collection of induced pluripotent stem cell-derived cardiomyocyte cell lines. Under the Cardiovascular Diseases Research program (CFDA 93.837), Khloris will establish 50 cell lines from healthy individuals and patients with common hereditary cardiac disorders such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and long...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $361,083 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, OH. The grant supports research on how acetylation regulates the subcellular localization of the transcription factor YAP and its role in cardiac regeneration. The 5-year project aims to investigate how metabolic stresses affect YAP acetylation through the NAD+/SIRT1/2 axis, and whether...